The June Gauntlet: 14 Deals, $35B, 5 Weeks

June 2026 is shaping up to be the busiest month in merger arbitrage this year. Fourteen active deals in the ArbLens tracker have June close dates — $35 billion in combined deal value about to resolve. Outside dates expiring, shareholder votes scheduled, regulators deciding. Here's every deal that matters and what to watch.

Issue #1 ranked deals by spread. Issue #2 ranked by risk-reward. This week we're doing something different: looking at the deals on a clock. When you track 53 active deals, the most important question isn't always "which has the widest spread" — it's "which ones are about to resolve, and what happens when they do?"

Across the full ArbLens tracker, the deal pipeline breaks down like this: 14 targeting June close, 13 in Q3, 19 in Q4, and 7 stretching into 2027. June's cluster is unusually dense — and it contains several deals with hard binary catalysts where we'll know the outcome within days, not months.

These deals have specific dates or decisions arriving in the next few weeks. The spread either collapses to zero or blows out. No in-between.

All major approvals obtained: 96% shareholder vote, Competition Bureau no-action letter, BC Supreme Court final order. The outside date is June 1, 2026 — nine days from today. Either the deal closes in the next week and a half, or Robinhood extends the outside date again (AGM already extended to July 2). This is as binary as it gets. The 7.5% spread at C$0.34 is pure event risk.

Two binary catalysts on the same day. Cintas withdrew and refiled HSR on May 12, resetting the antitrust clock — it expires June 11. The shareholder vote is also June 11. The Croatti family controls 66.7% of voting power and has not publicly committed to vote for. At 8.7% spread, the market is pricing real uncertainty about whether the family will approve. If both clear on June 11, the spread evaporates. If either fails, this deal is dead.

Tender offer expiration date of June 10. Chiesi's largest acquisition ever. EKTERLY (sebetralstat) is the first oral on-demand HAE therapy. The 0.8% spread is tight — the market expects this to close cleanly. Foreign investment clearances are the only wrinkle (Chiesi is Italian). Near-zero spread means this is a capital-parking play, not an arb opportunity.

These deals have all or most approvals secured and are expected to close in June. Spreads are thin because the market agrees.

These deals have June close dates but face meaningful remaining conditions. The spreads are wider because the outcome is less certain.

For context, here's what's behind the June cluster: 13 deals targeting Q3 ($192B combined value, including the $110B WBD mega-deal and $55B EA take-private), 19 in Q4 ($190B, including the $48.7B KVUE/KMB combination and $22B EQH/CRBG insurance merger), and 7 stretching into 2027 ($169B, anchored by the $85B NSC/UNP railroad merger). The arb calendar stays busy through year-end.